Skip to main content

Table 1 Baseline characteristics in 22 patients. Values are reported as frequency (n [%]) or as mean (range)

From: The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China

Characteristic Number of patients (percent)
Age, yrs
 Median age (range) 55 (39–77)
 ≤ 55 12 (54.5)
 > 55 10 (45.5)
Primary tumor location
 Ovary 21 (95.5)
 Fallopian tube 1 (4.5)
International FIGO stage
 II 2 (9.1)
 III 11 (50.0)
 IV 8 (36.4)
 Unknown 1 (4.5)
Histological type
 High-grade serous 19 (86.4)
 Low-grade serous 1 (4.5)
 Other 1 (4.5)
 Unknown 1 (4.5)
Family history of cancer
 Yes 9 (40.9)
 No 13 (59.1)
ECOG
 0 8 (36.4)
 1 13 (59.1)
 2 1 (4.5)
Baseline body weight
 ≥ 77 kg 0 (0)
 < 77 kg 22 (100)
Platelet count
 ≥ 150 × 109/L 12 (54.5)
 < 150 × 109/L 10 (45.5)
HRD status
 HRD-positive 6 (27.3)
  BRCA-mutated 1 (4.5)
  BRCA-wild type or BRCA-unknown and HRD-positive 5 (22.7)
 HRD-negative 8 (36.4)
 HRD unknown 8 (36.4)
Prior lines of chemotherapy
 ≤ 1 12 (54.5)
 > 1 10 (45.5)
Platinum status
 Platinum-sensitive 5 (22.7)
 Platinum-resistant 5 (22.7)
 Unknown 12 (54.5)
Categories of therapy
 First-line maintenance therapy 6 (27.3)
 Exploratory therapy 16 (72.7)
  Exploratory second-line maintenance therapy 1 (4.5)
  Exploratory front-line therapy 6 (27.3)
  Exploratory multi-line therapy 9 (40.9)
NACT+IDS
 Yes 7 (31.8)
 No 15 (68.2)
Primary debulking surgery
 Yes 12 (54.5)
 No 10 (45.5)
Secondary cytoreductive surgery
 Yes 3 (13.6)
 No 19 (86.4)
Combination with other agents
 Yes 4 (18.2)
 No 18 (81.8)
  1. Abbreviations: FIGO International Federation of Gynecology and Obstetrics, ECOG Eastern Cooperative Oncology Group, HRD homologous recombination deficiency, NACT Neoadjuvant chemotherapy, IDS Interval debulking surgery